Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 6, 2026, 3:35 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 267 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: L-cysteine Clear all
Not yet recruiting Early Phase 1 Interventional Accepts healthy volunteers

The MIND Study: The MGH/MIT Investigation of NAC on Dysregulation

NCT07323446
View directory record Official record
Conditions
Emotional Dysregulation
Interventions
N-Acetyl Cysteine (NAC), Placebo
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
6 Years to 12 Years
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2027 – 2030
U.S. locations
2
States / cities
Boston, Massachusetts • Cambridge, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 16, 2026 · Synced Sep 6, 2026, 3:35 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Antioxidant Therapy With N-acetylcysteine for Children With Neurofibromatosis Type 1

NCT04481048
View directory record Official record
Conditions
Neurofibromatosis 1
Interventions
N-Acetyl cysteine, Placebo
Drug · Other
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
8 Years to 16 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2024
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 4, 2026 · Synced Sep 6, 2026, 3:35 PM EDT
Terminated Phase 2 Interventional Results available

MemoryXL Effects on Mild Cognitive Impairment Patients

NCT00903695
View directory record Official record
Conditions
Mild Cognitive Impairment
Interventions
Memory XL, placebo
Drug
Lead sponsor
University of Oklahoma
Other
Eligibility
55 Years to 85 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
2
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Jan 25, 2012 · Synced Sep 6, 2026, 3:35 PM EDT
Recruiting Phase 1Phase 2 Interventional

Effect of NAC on Preventing Chemo-Related Cognitive Impairments in Ovarian Ca Pts Treated W/ PBT

NCT04520139
View directory record Official record
Conditions
Ovarian Cancer, Cognitive Impairment
Interventions
N-Acetyl-Cysteine, Placebo
Drug · Other
Lead sponsor
University of California, Irvine
Other
Eligibility
18 Years and older · Female only
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Orange, California
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Sep 6, 2026, 3:35 PM EDT
Active, not recruiting Not applicable Interventional

Obstructive Sleep Apnea (OSA) and Sex-Specific Responses to N-acetylcysteine (NAC)

NCT06311045
View directory record Official record
Conditions
Obstructive Sleep Apnea
Interventions
N-acetylcysteine (NAC), Placebo, Positive Airway Pressure (PAP) Therapy
Dietary Supplement · Procedure
Lead sponsor
NYU Langone Health
Other
Eligibility
55 Years to 75 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 23, 2026 · Synced Sep 6, 2026, 3:35 PM EDT
Completed Not applicable Interventional Results available

Glutathione Metabolism in Adolescents With Type 1 Diabetes - Study A

NCT00858897
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
Cysteine isotope infusion at normoglycemia vs hyperglycemia, Regular Insulin
Other · Drug
Lead sponsor
Nemours Children's Clinic
Other
Eligibility
14 Years to 18 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Jul 9, 2023 · Synced Sep 6, 2026, 3:35 PM EDT
Completed Not applicable Interventional Results available

The Effect of N-Acetyl-L-Cysteine, on Inflammatory and Oxidative Stress Markers in Pulmonary Sarcoidosis

NCT01587001
View directory record Official record
Conditions
Pulmonary Sarcoidosis
Interventions
N-acetyl-cysteine, Placebo
Dietary Supplement · Drug
Lead sponsor
National Jewish Health
Other
Eligibility
18 Years to 80 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Nov 3, 2020 · Synced Sep 6, 2026, 3:35 PM EDT
Completed Early Phase 1 Interventional

Functional Magnetic Resonance Imaging of N-acetylcysteine in Cocaine Dependence

NCT02994875
View directory record Official record
Conditions
Cocaine Dependence
Interventions
N-acetylcysteine, Placebo
Dietary Supplement · Other
Lead sponsor
Yale University
Other
Eligibility
18 Years to 65 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Oct 4, 2020 · Synced Sep 6, 2026, 3:35 PM EDT
Terminated Phase 3 Interventional Results available

NAC for Head Trauma-induced Anosmia

NCT03680911
View directory record Official record
Conditions
Anosmia, Head Trauma
Interventions
N Acetyl Cysteine, Placebo oral capsule
Drug
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Feb 3, 2021 · Synced Sep 6, 2026, 3:35 PM EDT
Completed Phase 2 Interventional Results available

An Open-Label Study of N-Acetyl Cysteine in Children With Autism

NCT00676195
View directory record Official record
Conditions
Autistic Disorder
Interventions
N-Acetyl Cysteine
Drug
Lead sponsor
Stanford University
Other
Eligibility
3 Years to 12 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Mar 28, 2017 · Synced Sep 6, 2026, 3:35 PM EDT
Withdrawn Phase 1Phase 2 Interventional

Inhaled NAC in Treatment of IPF

NCT03720483
View directory record Official record
Conditions
Idiopathic Pulmonary Fibrosis (IPF)
Interventions
N-acetyl cysteine then Placebo, Placebo then N-acetyl cysteine
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
40 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Jun 7, 2021 · Synced Sep 6, 2026, 3:35 PM EDT
Completed Phase 2 Interventional Results available

A Study of Oxidative Pathways in MS Fatigue

NCT02804594
View directory record Official record
Conditions
Progressive Multiple Sclerosis, Fatigue
Interventions
N-acetyl cysteine, Placebo
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 75 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jul 29, 2026 · Synced Sep 6, 2026, 3:35 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Determine the Safety, Tolerability, and Pharmacokinetic Profile of HPN-07 and HPN-07 Plus NAC

NCT02259595
View directory record Official record
Conditions
Hearing Loss, Sensorineural Hearing Loss, Noise-Induced Hearing Loss
Interventions
HPN-07, NAC, Placebo
Drug
Lead sponsor
Otologic Pharmaceutics, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Raleigh, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 30, 2015 · Synced Sep 6, 2026, 3:35 PM EDT
Recruiting Phase 2Phase 3 Interventional

Targeting the Neurobiology of RRB in Autism Using N-acetylcysteine: Trial

NCT05664789
View directory record Official record
Conditions
Autism Spectrum Disorder
Interventions
N acetyl cysteine, Placebo
Drug
Lead sponsor
Stanford University
Other
Eligibility
3 Years to 12 Years
Enrollment
144 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated May 14, 2026 · Synced Sep 6, 2026, 3:35 PM EDT
Completed Phase 3 Interventional Results available

Prevention of Serious Adverse Events Following Angiography

NCT01467466
View directory record Official record
Conditions
Acute Renal Failure, Kidney Disease, Coronary Artery Disease
Interventions
IV isotonic saline, IV isotonic bicarbonate, N-acetylcysteine, Placebo
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
5,177 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
35
States / cities
Tucson, Arizona • Little Rock, Arkansas • Palo Alto, California + 32 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2025 · Synced Sep 6, 2026, 3:35 PM EDT
Terminated Phase 2 Interventional Results available

Effect of Acetylcysteine With Topotecan Hydrochloride on the Tumor Microenvironment in Patients With Persistent or Recurrent High Grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

NCT02569957
View directory record Official record
Conditions
Malignant Ovarian Endometrioid Tumor, Malignant Ovarian Serous Tumor, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma
Interventions
Topotecan Hydrochloride, Acetylcysteine
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Other
Eligibility
18 Years and older · Female only
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 3, 2025 · Synced Sep 6, 2026, 3:35 PM EDT
Completed Phase 1 Interventional

Se-Methyl-Seleno-L- Cysteine (MSC) in Treating Healthy Patients

NCT00489372
View directory record Official record
Conditions
Healthy, no Evidence of Disease
Interventions
Se-methyl-seleno-L-cysteine, placebo, pharmacological study, laboratory biomarker analysis
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 70 Years · Male only
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
2
States / cities
Chicago, Illinois • Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Nov 13, 2014 · Synced Sep 6, 2026, 3:35 PM EDT
Completed Phase 1 Interventional Results available

SXC-2023 Cocaine Interaction Study

NCT06343532
View directory record Official record
Conditions
Cocaine Use Disorder
Interventions
SXC-2023, SXC-2023 Placebo
Drug
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
18 Years to 59 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Apr 23, 2026 · Synced Sep 6, 2026, 3:35 PM EDT
Completed Phase 1 Interventional

Study of the Safety and Tolerability of ALTH12 Versus Mesalamine Enema in Subjects With Left-Sided Ulcerative Colitis

NCT01020708
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
mesalamine, ALTH12-1:4, ALTH12-2:4
Drug
Lead sponsor
Altheus Therapeutics, Inc.
Industry
Eligibility
18 Years to 64 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Mar 28, 2011 · Synced Sep 6, 2026, 3:35 PM EDT
Recruiting Phase 3 Interventional

Prefrontal Glutamatergic Modulation by NAC and MBCT for Depression in Youth

NCT07464886
View directory record Official record
Conditions
Mild Depression
Interventions
N-acetylcysteine, Mindfulness-based cognitive therapy, Placebo, Sham mindfulness-based intervention
Drug · Behavioral
Lead sponsor
University of Cincinnati
Other
Eligibility
15 Years to 24 Years
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 10, 2026 · Synced Sep 6, 2026, 3:35 PM EDT
Completed Phase 4 Interventional

Safety of Low Dose IV Contrast CT Scanning in Chronic Kidney Disease

NCT02476526
View directory record Official record
Conditions
Chronic Kidney Disease, Pulmonary Embolism, Renal Artery Stenosis, Pulmonary Cancer
Interventions
Low Volume iso-osmolar non-ionic radio contrast medium, Acetylcysteine Inhalation, Sodium Bicarbonate Solution, 64-MDCT Scanning
Drug · Procedure
Lead sponsor
VA Greater Los Angeles Healthcare System
Federal
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2017
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Nov 27, 2017 · Synced Sep 6, 2026, 3:35 PM EDT
Terminated Early Phase 1 Interventional Accepts healthy volunteers

Antioxidant Use in Diabetes to Reduce Oxidative Stress

NCT03056014
View directory record Official record
Conditions
Ameliorating Oxidative Stress in Type 1 Diabetes
Interventions
N-acetyl cysteine, omega 6 Fish oil ( PUFA), Placebo
Drug · Dietary Supplement
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 44 Years · Female only
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 21, 2022 · Synced Sep 6, 2026, 3:35 PM EDT
Withdrawn Early Phase 1 Interventional

The Role of Glutathione Deficiency and MSIDS Variables in Long COVID-19

NCT05371288
View directory record Official record
Conditions
COVID-19
Interventions
NAC (N-acetyl cysteine), Alpha lipoic acid (ALA), liposomal glutathione (GSH)
Drug
Lead sponsor
University of California, Irvine
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
Orange, California
Source: ClinicalTrials.gov public record
Updated Nov 4, 2024 · Synced Sep 6, 2026, 3:35 PM EDT
Completed Early Phase 1 Interventional Results available

NAC +taVNS in IDM Who Are Poor Oral Feeders

NCT04632069
View directory record Official record
Conditions
Infant of Diabetic Mother, Oxidative Stress, Vagus Nerve Stimulation, Feeding Disorders
Interventions
N acetyl cysteine + vagus nerve stimulation
Combination Product
Lead sponsor
Medical University of South Carolina
Other
Eligibility
3 Weeks to 5 Months
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Aug 28, 2024 · Synced Sep 6, 2026, 3:35 PM EDT